A new insight into the role of EVO as a potential anticancer agent for treatment of human renal carcinoma via stimulated JNK- and PERK-mediated phosphorylation of the Bcl-2 protein leading to disruption of the mitochondrial membrane potential was provided herein. Here, EIF2AK3 is linked to renal carcinoma.